Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
暂无分享,去创建一个
[1] R. Anwyl,et al. β‐amyloid inhibition of long‐term potentiation is mediated via tumor necrosis factor , 2005 .
[2] S. Stahl. Cholinesterase inhibitors for Alzheimer's disease. , 1998, Hospital practice.
[3] K. Herholz,et al. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type , 1992, Neurobiology of Aging.
[4] P. Tariot,et al. Meta-analysis of 6-month memantine clinical trials in Alzheimer’s disease , 2005, Alzheimer's & Dementia.
[5] O. Arancio,et al. Fibrillar beta-amyloid impairs the late phase of long term potentiation. , 2006, Current Alzheimer research.
[6] S. Ozturk,et al. Magnesium supplementation in the treatment of dementia patients. , 2006, Medical hypotheses.
[7] C. Cotman,et al. Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. , 1991, Neuroreport.
[8] G. Collingridge,et al. Effects of memantine and MK‐801 on NMDA‐induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices , 1996, British journal of pharmacology.
[9] S. Lipton. Turning down, but not off , 2004, Nature.
[10] R. Anwyl,et al. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. , 1995, Neuroreport.
[11] S. Gauthier,et al. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies , 2005, International journal of geriatric psychiatry.
[12] R. Busto,et al. Excitotoxic index — a biochemical marker of selective vulnerability , 1991, Neuroscience Letters.
[13] J. Durlach. Magnesium depletion and pathogenesis of Alzheimer's disease. , 1990, Magnesium research.
[14] R. Porter,et al. Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential , 1995, Journal of neurochemistry.
[15] A. Novelli,et al. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.
[16] A. Mitani,et al. Selective vulnerability of hippocampal CA1 neurons cannot be explained in terms of an increase in glutamate concentration during ischemia in the gerbil: Brain microdialysis study , 1992, Neuroscience.
[17] M. Furr,et al. Cerebrospinal fluid and serum concentrations of ponazuril in horses. , 2001, Veterinary therapeutics : research in applied veterinary medicine.
[18] W. Klein,et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.
[19] M. Mattson,et al. Impairment of Glucose and Glutamate Transport and Induction of Mitochondrial Oxidative Stress and Dysfunction in Synaptosomes by Amyloid β‐Peptide: Role of the Lipid Peroxidation Product 4‐Hydroxynonenal , 1997, Journal of neurochemistry.
[20] R. Nitsch,et al. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type , 2005, Journal of Neural Transmission.
[21] G. Westbrook,et al. The time course of glutamate in the synaptic cleft. , 1992, Science.
[22] G. Cortopassi,et al. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[23] W. Klein,et al. Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.
[24] Brett Chromy,et al. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.
[25] H. Hirai,et al. Molecular Determinants of Agonist Discrimination by NMDA Receptor Subunits: Analysis of the Glutamate Binding Site on the NR2B Subunit , 1997, Neuron.
[26] A. Periclou,et al. Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil , 2004, The Annals of pharmacotherapy.
[27] A. Floden,et al. β-Amyloid-Stimulated Microglia Induce Neuron Death via Synergistic Stimulation of Tumor Necrosis Factor α and NMDA Receptors , 2005, The Journal of Neuroscience.
[28] W. Danysz,et al. The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. , 1999, The Journal of pharmacology and experimental therapeutics.
[29] R. Busto,et al. Comparative Effect of Transient Global Ischemia on Extracellular Levels of Glutamate, Glycine, and γ‐Aminobutyric Acid in Vulnerable and Nonvulnerable Brain Regions in the Rat , 1991, Journal of neurochemistry.
[30] G. Mealing,et al. Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. , 1996, European journal of pharmacology.
[31] E. Loveman,et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease , 2006, International journal of geriatric psychiatry.
[32] G. Collingridge,et al. Low-frequency activation of the NMDA receptor system can prevent the induction of LTP , 1989, Neuroscience Letters.
[33] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[34] K. Jones,et al. Systemically administered N-methyl-D-aspartate interferes with acquisition of a passive avoidance response in rats , 1989, Pharmacology Biochemistry and Behavior.
[35] F. Sherriff,et al. Memantine for dementia. , 2005, The Cochrane database of systematic reviews.
[36] T. Manabe,et al. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction , 2001, The European journal of neuroscience.
[37] R. Henneberry. The role of neuronal energy in the neurotoxicity of excitatory amino acids , 1989, Neurobiology of Aging.
[38] M. Hallak. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. , 1998, Magnesium research.
[39] G. Wilcock,et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.
[40] Richard S. J. Frackowiak,et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.
[41] J. Olney,et al. Low Doses of Memantine Disrupt Memory in Adult Rats , 2006, The Journal of Neuroscience.
[42] B. Scatton,et al. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes , 1997, Neuroscience Letters.
[43] F. Schmitt,et al. Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.
[44] H. Xiong,et al. Activation of NR1a/NR2B receptors by soluble factors from APP-stimulated monocyte-derived macrophages: implications for the pathogenesis of Alzheimer’s disease , 2004, Neurobiology of Aging.
[45] L. Kaczmarek,et al. Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists , 1999, Neurotoxicity Research.
[46] A. Enz,et al. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain , 2004, Neuropharmacology.
[47] P. Andiné,et al. Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia. , 1991, Brain research. Developmental brain research.
[48] F Fazio,et al. Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease. , 1995, Dementia.
[49] C. Carter,et al. The pharmacology of native N-methtl-D-aspartate receptor subtypes: Different receptors control the release of different striatal and spinal transmitters , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[50] A. Maelicke,et al. Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.
[51] J. Kornhuber,et al. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man , 1995, Neuroscience Letters.
[52] W. Danysz,et al. Brain Penetration and In Vivo Recovery of NMDA Receptor Antagonists Amantadine and Memantine: A Quantitative Microdialysis Study , 1999, Pharmaceutical Research.
[53] R. Anwyl,et al. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. , 2004, Experimental gerontology.
[54] C. Ragan,et al. Modulation of 45Ca2+ Influx into Cells Stably Expressing Recombinant Human NMDA Receptors by Ligands Acting at Distinct Recognition Sites , 1996, Journal of neurochemistry.
[55] Adam M. Campbell,et al. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane , 2006, Pharmacology Biochemistry and Behavior.
[56] R. Bullock. Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date , 2006, Alzheimer disease and associated disorders.
[57] W. Wesemann,et al. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. , 1980, Journal of neural transmission. Supplementum.
[58] T. Rammsayer,et al. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. , 2001, Learning & memory.
[59] P. Carlier,et al. Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes. , 1999, British journal of clinical pharmacology.
[60] W. Danysz,et al. Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats , 2005, Psychopharmacology.
[61] O. Krishtal,et al. Comparative Patch‐clamp Studies with Freshly Dissociated Rat Hippocampal and Striatal Neurons on the NMDA Receptor Antagonistic Effects of Amantadine and Memantine , 1996, The European journal of neuroscience.
[62] Correlation between cerebral blood flow values obtained by Xenon/CT and Kety‐Schmidt (N2O) methods , 1996, Acta neurologica Scandinavica. Supplementum.
[63] Roger Anwyl,et al. Synaptic plasticity in animal models of early Alzheimer's disease. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[64] Steven G Potkin,et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[65] C. Parsons,et al. Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo , 1994, Neuroscience Letters.
[66] G. Collingridge,et al. Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism , 1986, Nature.
[67] S. Lipton. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.
[68] B. Reisberg,et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. , 2002, Journal of neural transmission. Supplementum.
[69] K. Grant,et al. Dizocilpine-like Discriminative Stimulus Effects of Low-affinity Uncompetitive NMDA Antagonists , 1996, Neuropharmacology.
[70] C. Parsons,et al. Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. , 1996, European journal of pharmacology.
[71] C. Parsons,et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies , 1997, Neuroscience & Biobehavioral Reviews.
[72] J. C. Chisholm,et al. The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. , 1995, Journal of neurobiology.
[73] C. Parsons,et al. Glutamate in CNS disorders as a target for drug development: an update. , 1998, Drug news & perspectives.
[74] E. Mackenzie,et al. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[75] J. C. Torre,et al. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide , 2000, Brain Research Reviews.
[76] G. Collingridge,et al. Characterization of an N-methyl-d-aspartate receptor component of synaptic transmission in rat hippocampal slices , 1987, Neuroscience.
[77] T. Bliss,et al. Memories of NMDA receptors and LTP , 1995, Trends in Neurosciences.
[78] W. Danysz,et al. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration. , 1999, Behavioural pharmacology.
[79] A. Floden,et al. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[80] M. Weller,et al. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy , 1997, Biological Psychiatry.
[81] D. Selkoe,et al. Amyloid β-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation , 2004, Neuroscience Letters.
[82] C. Parsons,et al. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence , 2003, International journal of geriatric psychiatry.
[83] L. Schneider,et al. Severe Impairment Battery: A Potential Measure for AD Clinical Trials , 1997 .
[84] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[85] M. Rogawski,et al. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D- aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. , 1991, The Journal of pharmacology and experimental therapeutics.
[86] K. Ditzler. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.
[87] P. Deyn,et al. Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model , 2006, European Neuropsychopharmacology.
[88] C. Parsons,et al. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) , 1993, Neuropharmacology.
[89] C. Parsons,et al. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP , 1997, Neuropharmacology.
[90] C. Parsons,et al. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones , 2001, Neuropharmacology.
[91] N. Newberry,et al. Inhibition of human α7 nicotinic acetylcholine receptors by open channel blockers of N‐methyl‐D‐aspartate receptors , 2003 .
[92] M. Smith,et al. CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains. , 1998, Neuroscience letters.
[93] A. Buisson,et al. Striatal Protection Induced by Lesioning the Substantia Nigra of Rats Subjected to Focal Ischemia , 1992, Journal of neurochemistry.
[94] M. Rogawski,et al. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. , 1993, Trends in pharmacological sciences.
[95] S. L. Mobley,et al. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat , 1994, Brain Research.
[96] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[97] D. Teplow,et al. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease , 2004, Neurobiology of Aging.
[98] A. Sobolevsky,et al. Interaction of memantine and amantadine with agonist‐unbound NMDA‐receptor channels in acutely isolated rat hippocampal neurons , 1998, The Journal of physiology.
[99] L. Nowak,et al. Magnesium gates glutamate-activated channels in mouse central neurones , 1984, Nature.
[100] P. V. Rayudu,et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation , 1998, Neuroscience.
[101] L. Ye,et al. Suppressive action produced by β-amyloid peptide fragment 31–35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: it's offset by (−)huperzine A , 1999, Neuroscience Letters.
[102] E. Andrási,et al. Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease. , 2000, Magnesium research.
[103] J. Miguel-Hidalgo,et al. Memantine inhibits the expression of caspase‐8 and improves learning in rats injected with [beta]‐amyloid (A[beta]1–40) , 2006 .
[104] J. C. de la Torre. Impaired brain microcirculation may trigger Alzheimer's disease. , 1994, Neuroscience and biobehavioral reviews.
[105] F. J. Marshall,et al. THE ADAMANTYL GROUP IN MEDICINAL AGENTS. I. HYPOGLYCEMIC N-ARYLSULFONYL-N' -ADAMANTYLUREAS. , 1963, Journal of medicinal chemistry.
[106] C. Parsons,et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo , 1995, Neuropharmacology.
[107] R. Albin,et al. Alternative excitotoxic hypotheses , 1992, Neurology.
[108] Dominic M. Walsh,et al. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.
[109] S. Tkachenko,et al. Neuroprotective and Cognition‐Enhancing Properties of MK‐801 Flexible Analogs , 2001, Annals of the New York Academy of Sciences.
[110] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[111] D. Wilcock,et al. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice , 2005, BMC Neuroscience.
[112] A. Parpura-Gill,et al. The inhibitory effects of β-amyloid on glutamate and glucose uptakes by cultured astrocytes , 1997, Brain Research.
[113] J. Olin,et al. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[114] T. Taniwaki,et al. Positron emission tomographic (PET) studies in dementia , 1993, Journal of the Neurological Sciences.
[115] J. Olin,et al. Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil: An Exploratory Reanalysis , 2006, Alzheimer disease and associated disorders.
[116] Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.
[117] D. Selkoe,et al. Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.
[118] M. Mattson,et al. Secreted amyloid precursor protein α selectively suppresses N-methyl-d-aspartate currents in hippocampal neurons: involvement of cyclic GMP , 1998, Neuroscience.
[119] R. Anwyl,et al. β-Amyloid-Mediated Inhibition of NMDA Receptor-Dependent Long-Term Potentiation Induction Involves Activation of Microglia and Stimulation of Inducible Nitric Oxide Synthase and Superoxide , 2004, The Journal of Neuroscience.
[120] W. Danysz,et al. Glutamate antagonists have different effects on spontaneous locomotor activity in rats , 1994, Pharmacology Biochemistry and Behavior.
[121] H S Chen,et al. Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.
[122] C. Parsons,et al. Budipine is a low affinity, N-methyl-d-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones , 1998, Neuropharmacology.
[123] S. Warach,et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[124] G. Lynch,et al. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5 , 1986, Nature.
[125] D. Cory-Slechta,et al. Lead exposure potentiates the effects of NMDA on repeated learning. , 1994, Neurotoxicology and teratology.
[126] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[127] R. Anwyl,et al. Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity , 2004, Experimental Gerontology.
[128] C. Parsons,et al. Modulation of learning processes by ionotropic glutamate receptor ligands. , 1995, Behavioural pharmacology.
[129] J. Glick. Dementias: the role of magnesium deficiency and an hypothesis concerning the pathogenesis of Alzheimer's disease. , 1990, Medical hypotheses.
[130] H. Tanila,et al. Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.
[131] W. Abraham,et al. Effects of the NMDA receptor/channel antagonists CPP and MK801 on hippocampal field potentials and long-term potentiation in anesthetized rats , 1988, Brain Research.
[132] M. Knipper,et al. Developmental Regulation of Nicotinic Synapses on Cochlear Inner Hair Cells , 2004, The Journal of Neuroscience.
[133] L. Mucke,et al. Amyloid Protein Precursor Stimulates Excitatory Amino Acid Transport , 1998, The Journal of Biological Chemistry.
[134] Mark P. Mattson,et al. β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease , 1993, Trends in Neurosciences.
[135] C. Parsons,et al. The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner , 2001, Neuroscience Letters.
[136] M. Bardgett,et al. Magnesium deficiency impairs fear conditioning in mice , 2005, Brain Research.
[137] V. Ingram,et al. A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue. , 1993, Neuroreport.
[138] W. Danysz,et al. Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion. , 1996, European journal of pharmacology.
[139] W. Danysz,et al. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. , 1996, Neuroreport.
[140] D. Lodge,et al. Differences in results from in vivo and in vitro studies on the use-dependency of N-methylaspartate antagonism by MK-801 and other phencyclidine receptor ligands. , 1988, European journal of pharmacology.
[141] N. Newberry,et al. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. , 2003, British journal of pharmacology.
[142] C. Herron,et al. The role of c-Jun N-terminal kinase in the Aβ-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus , 2004, Neuropharmacology.
[143] J. Blass,et al. Inherent Abnormalities in Energy Metabolism in Alzheimer Disease: Interaction with Cerebrovascular Compromise , 2000, Annals of the New York Academy of Sciences.
[144] E. Mackenzie,et al. NMDA Receptor Activation Inhibits α-Secretase and Promotes Neuronal Amyloid-β Production , 2005, The Journal of Neuroscience.
[145] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[146] D. Bertrand,et al. Open-Channel Blockers at the Human α4β2 Neuronal Nicotinic Acetylcholine Receptor , 1998 .
[147] E. Bigio,et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.
[148] J. O'Brien,et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology , 2006, Journal of psychopharmacology.
[149] M. Maggini,et al. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease , 2005, European Journal of Clinical Pharmacology.
[150] S. Hartmann,et al. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy , 2003, International clinical psychopharmacology.
[151] J. Crawford. Alzheimer's disease risk factors as related to cerebral blood flow. , 1996, Medical hypotheses.
[152] Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol , 2001, Neuroscience Letters.
[153] M. Beal,et al. The role of mitochondria in inherited neurodegenerative diseases , 2006, Journal of neurochemistry.
[154] N. Herrmann,et al. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease , 2004, Expert opinion on drug safety.
[155] C. Herron,et al. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. , 2001, Journal of neurophysiology.
[156] H. Benveniste,et al. Elevation of the Extracellular Concentrations of Glutamate and Aspartate in Rat Hippocampus During Transient Cerebral Ischemia Monitored by Intracerebral Microdialysis , 1984, Journal of neurochemistry.
[157] R. Anwyl,et al. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. , 2005, The European journal of neuroscience.
[158] L. Provinciali,et al. Modifications of platelet from Alzheimer disease patients: A possible relation between membrane properties and NO metabolites , 2007, Neurobiology of Aging.
[159] Jon W. Johnson,et al. Mechanism of action of memantine. , 2006, Current opinion in pharmacology.
[160] S. Ferris. Evaluation of memantine for the treatment of Alzheimer’s disease , 2003, Expert opinion on pharmacotherapy.
[161] W. Wesemann,et al. Distribution of memantine in brain, liver, and blood of the rat. , 1982, Arzneimittel-Forschung.
[162] F. Bricaire,et al. Neurodegenerative diseases and oxidative stress. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[163] R. Anwyl,et al. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. , 2005, Biochemical Society transactions.
[164] J. Greenamyre. Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease: “Use it and lose it” , 1991, Neurobiology of Aging.
[165] A. Maelicke,et al. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. , 2005, The Journal of pharmacology and experimental therapeutics.
[166] C. Parsons,et al. Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes , 2008, Journal of Neural Transmission.
[167] John M. Lee,et al. Reduced High-Affinity Agonist Binding at the M1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations , 1999, Experimental Neurology.
[168] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[169] W. Honer,et al. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease , 1994, Annals of neurology.
[170] J. Bormann. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. , 1989, European journal of pharmacology.
[171] C. Parsons,et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization , 1999, Neuropharmacology.
[172] M. Sarazin,et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment , 2005, International journal of clinical practice.
[173] M. Beal,et al. Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.
[174] J. Levine,et al. A Transient Receptor Potential Vanilloid 4-Dependent Mechanism of Hyperalgesia Is Engaged by Concerted Action of Inflammatory Mediators , 2006, The Journal of Neuroscience.
[175] D. Clifford,et al. Low concentrations of N-methyl-d-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices , 1992, Neuroscience Letters.
[176] R. Spanagel,et al. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. , 1994, European journal of pharmacology.
[177] C. Parsons,et al. Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action , 2009, Neurotoxicity Research.
[178] A. Sobolevsky,et al. Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels. , 1998, Biophysical journal.
[179] G. Collingridge,et al. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells , 1996, British journal of pharmacology.
[180] W Blaine Stine,et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.
[181] S. Shimohama,et al. Cl−-ATPase and Na+/K+-ATPase activities in Alzheimer's disease brains , 1998, Neuroscience Letters.
[182] J. Ruppersberg,et al. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. , 2001, Molecular pharmacology.
[183] G J Brewer,et al. Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β‐Amyloid in Rat Hippocampal Neurons , 2000, Journal of neurochemistry.
[184] R. Spanagel,et al. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. , 1995, Journal of neural transmission. Supplementum.
[185] D. Choi. Excitotoxic cell death. , 1992, Journal of neurobiology.
[186] V. Ingram,et al. Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. , 2002, Biochemical and biophysical research communications.
[187] W. Abraham,et al. NMDA receptor regulation by amyloid-β does not account for its inhibition of LTP in rat hippocampus , 2003, Brain Research.
[188] C. Parsons,et al. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine , 2007, Neuropharmacology.
[189] N. Bogdanovic,et al. Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age‐matched control but similarity to the rat model , 2002, FEBS letters.
[190] S. Lipton. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. , 2005, Current Alzheimer research.
[191] T. Golde. Disease modifying therapy for AD? 1 , 2006, Journal of neurochemistry.
[192] O. Ekenna,et al. Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. , 1982, Arzneimittel-Forschung.
[193] S. Elders,et al. The 'Severe Impairment Battery': assessing cognitive ability in adults with Down syndrome. , 1998, The British journal of clinical psychology.
[194] P. Keller,et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.
[195] M. Riepe,et al. Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .
[196] C. Parsons,et al. Different binding affinities of NMDA receptor channel blockers in various brain regions—Indication of NMDA receptor heterogeneity , 1995, Neuropharmacology.
[197] E. Giacobini,et al. Alzheimer disease, from molecular biology to therapy. , 1997, Advances in experimental medicine and biology.
[198] Jon W. Johnson,et al. Trapping channel block of NMDA-activated responses by amantadine and memantine. , 1997, Journal of neurophysiology.
[199] P. Landfield,et al. Chronically elevating plasma Mg2+ improves hippocampal frequency potentiation and reversal learning in aged and young rats , 1984, Brain Research.
[200] R. Nitsch,et al. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: A cross-sectional comparison against advanced late-onset and incipient early-onset cases , 1991, Journal of neural transmission. Parkinson's disease and dementia section.
[201] W. Danysz,et al. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition , 2000, Experimental Brain Research.
[202] P. Deyn,et al. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model , 2005, Psychopharmacology.
[203] Dominic M. Walsh,et al. Certain Inhibitors of Synthetic Amyloid β-Peptide (Aβ) Fibrillogenesis Block Oligomerization of Natural Aβ and Thereby Rescue Long-Term Potentiation , 2005, The Journal of Neuroscience.
[204] B. Trommer,et al. Long-term depression at the medial perforant path-granule cell synapse in developing rat dentate gyrus. , 1996, Brain research. Developmental brain research.
[205] I. Daum,et al. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans , 1997, Neuroscience Letters.
[206] C. Parsons,et al. Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices , 1999, Neuropharmacology.
[207] R. Anwyl,et al. Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.
[208] G. Mealing,et al. Differences in degree of trapping between AR-R15896 and other uncompetitive NMDA receptor antagonists , 2000, Amino Acids.
[209] S. Lipton,et al. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine , 2004, Cell Death and Differentiation.
[210] R. Anwyl,et al. Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.
[211] C. Barnes,et al. Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats , 1996, The European journal of neuroscience.
[212] J. Kornhuber,et al. [3H]MK-801 binding sites in post-mortem human frontal cortex. , 1989, European journal of pharmacology.
[213] B. Clark,et al. Unsuspected morbid hypermagnesemia in elderly patients. , 1992, American journal of nephrology.
[214] B. Sakmann,et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.
[215] S. Akbarian,et al. Developmental and regional expression pattern of a novel NMDA receptor- like subunit (NMDAR-L) in the rodent brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[216] S. Hoyer,et al. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.
[217] S. Hoyer. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update , 2000, Experimental Gerontology.
[218] S. Vicini,et al. Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons , 1998, The European journal of neuroscience.
[219] G. Quack,et al. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. , 1993, Pharmacology & toxicology.
[220] M. Papp,et al. Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats , 1996, Pharmacology Biochemistry and Behavior.
[221] Patrizia Mecocci,et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.
[222] M. Rogawski,et al. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. , 2006, CNS drug reviews.
[223] Gordon W. Gifford,et al. Motherhood improves learning and memory , 1999, Nature.
[224] J. Kemp,et al. State‐dependent NMDA receptor antagonism by Ro 8‐4304, a novel NR2B selective, non‐competitive, voltage‐independent antagonist , 1998, British journal of pharmacology.
[225] H. Nakanishi,et al. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide , 1999, Neuroscience.
[226] T. Nabeshima,et al. Effects of memantine and donepezil on amyloid β-induced memory impairment in a delayed-matching to position task in rats , 2005, Behavioural Brain Research.
[227] Pierre N Tariot,et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.
[228] P. Banerjee,et al. Comments on “Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-d-aspartate Receptors in Rat Hippocampal Neurons” , 2005, Journal of Pharmacology and Experimental Therapeutics.
[229] C. Parsons,et al. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. , 2006, Behavioural pharmacology.
[230] H. Hirai,et al. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[231] T. Shimahara,et al. Alzheimer Amyloid β-Peptide Inhibits the Late Phase of Long-Term Potentiation through Calcineurin-Dependent Mechanisms in the Hippocampal Dentate Gyrus , 2002, Neurobiology of Learning and Memory.
[232] V. Ferraz,et al. Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test , 2006, Pharmacology Biochemistry and Behavior.
[233] D. Butterfield,et al. Amyloid beta-peptide inhibits Na+-dependent glutamate uptake. , 1999, Life sciences.
[234] T. Oda,et al. Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. , 2002, Japanese journal of pharmacology.
[235] J. D. L. Torre. Impaired brain microcirculation may trigger Alzheimer's disease , 1994, Neuroscience & Biobehavioral Reviews.
[236] Nathan Herrmann,et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[237] P. Keller,et al. Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .
[238] 野村 泉美. Mechanism of impairment of long-term potentiation by amyloid β is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons , 2008 .
[239] H. Ksiȩżak-Reding,et al. Ca2+ and Mg2+ selectively induce aggregates of PHF‐tau but not normal human tau , 1999, Journal of neuroscience research.
[240] Burton S. Rosner,et al. Neuropharmacology , 1958, Nature.
[241] Aung Si,et al. Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (Apis mellifera) , 2004, Pharmacology Biochemistry and Behavior.
[242] Shizuo Nakamura,et al. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. , 2006, European journal of pharmacology.
[243] S. Heinemann,et al. α10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.